In exchange for discounts to list prices on select medicines, the companies will receive relief from potential pharmaceutical tariffs over a three-year period.
The milestone supports a Phase III cancer immunotherapy program and marks a capacity expansion aimed at late-stage and commercial supply at its Stirling, Scotland site.
